Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-50
SponsorWright State University
About this trial
The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).
Eligibility criteria
Qualifiers
Female and Male adult subjects age 18 to 50
Must be able to give informed consent
Have access to stable transportation
All skin types on Fitzpatrick Scale (Type I-VI)
Disqualifiers
Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)
Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS [except for low-dose aspirin] or steroids)
Utilizing imipramine or any other tricyclic antidepressant (oral or cream)
Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)
Trial design
Treatments tested in this trial
- 4% Imipramine Cream
- Base Cream
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov